Cholera Vaccines Market by Type (Inactivated Vaccine, Live Attenuated Vaccine), Method of Administration (Injectable Vaccines, Oral Vaccines), End User, Age Group - Global Forecast 2024-2030

Cholera Vaccines Market by Type (Inactivated Vaccine, Live Attenuated Vaccine), Method of Administration (Injectable Vaccines, Oral Vaccines), End User, Age Group - Global Forecast 2024-2030

The Cholera Vaccines Market size was estimated at USD 286.42 million in 2023 and expected to reach USD 307.02 million in 2024, at a CAGR 7.32% to reach USD 469.83 million by 2030.

Cholera vaccines are biological preparations designed to protect individuals from cholera, a severe diarrheal illness caused by the Vibrio cholerae bacteria. These vaccines stimulate the body's immune response, enabling it to quickly recognize and combat the cholera bacteria if exposed. There are several types of cholera vaccines available, including both oral and injectable forms, each with varying degrees of effectiveness and duration of immunity. The use of cholera vaccines has expanded considerably owing to the global increase in travel to areas where cholera is endemic, which has heightened the need for preventive measures among travelers. Further, growing awareness and international support for global health initiatives have increased funding and logistical support for vaccination programs in vulnerable regions. However, the deployment of cholera vaccines faces several challenges. Logistical difficulties in distributing and administering vaccines in remote or resource-limited areas hinder widespread coverage. Additionally, the variability in vaccine-induced immunity, which can be influenced by factors such as age and the presence of pre-existing immunity, complicates the measurement of vaccine effectiveness in different populations. Despite these challenges, advances in vaccine technology, such as the development of single-dose vaccines or temperature-stable formulations, could significantly improve the practicality and effectiveness of vaccination campaigns. Moreover, integrating cholera vaccination programs with other public health initiatives could enhance overall disease control and promote more sustainable health improvements in affected regions.

Regional Insights

The cholera vaccine market exhibits distinct characteristics across various global regions, shaped by public health needs and socio-economic conditions. In America, there is demand among travelers and certain immigrant communities from cholera-endemic regions. Further, robust healthcare and sanitation systems across the region facilitate cholera vaccination programs. Europe has a significant adoption of cholera vaccines, majorly among travelers and military personnel deployed to endemic regions. The Middle East and Africa face higher risks and incidences of cholera, primarily attributed to poor sanitation and inadequate access to clean water, generating a need for cholera vaccines. Asia-Pacific observes a significant need for the cholera vaccine owing to higher prevalence rates in South and Southeast Asia. Countries such as India and Bangladesh are heavily impacted by cholera, largely driving the need in the region. The increasing awareness and government initiatives to control cholera outbreaks also support the steady consumption of these vaccines.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cholera Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Rising number of cholera cases across the globe
Supportive government promotional campaigns for cholera vaccination

Market Restraints

High cost of vaccine development coupled with issues of product shortages

Market Opportunities

Developments in recombinant DNA technology and cell-based production systems
Innovations in packaging and storage solutions for cholera vaccines

Market Challenges

Limited availability of skilled healthcare professionals worldwide

Market Segmentation Analysis

Type: Higher adoption of attenuated vaccines owing to their ability to stimulate strong immune responses
End User: Growing significance of Government vaccination programs, focusing on educating people about cholera prevention methods and the importance of vaccination

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cholera Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cholera Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Technology Transfer in Cholera Vaccination: A Partnership Between IVI and Biological E. Limited

South Korea's International Vaccine Institute (IVI) has initiated a technology transfer to Biological E. Limited (BE), an Indian vaccine and pharmaceutical company. This collaboration involves IVI providing BE with the necessary technical information, know-how, and materials to manufacture the simplified oral cholera vaccine (OCV-S) in India. This partnership intends to enhance the availability of affordable cholera vaccines for both the Indian market and globally.

Strategic Collaboration for Cholera Vaccine Production between GC Biopharma and Eubiologics

GC Biopharma, a South Korean biopharmaceutical company, has entered into a memorandum of understanding with Eubiologics to collaboratively produce the oral cholera vaccine, Euvichol. Under this agreement, Eubiologics will manage the bulk manufacturing phase of the vaccine, while GC Biopharma will handle the packaging tasks, including the bottling of the vaccine into vials, ensuring a streamlined process for vaccine supply.

TechInvention Introduces Innovative Cholera Vaccine Packaging in India with Eubiologics Partnership

Mumbai-based TechInvention Lifecare, in collaboration with South Korea's Eubiologics Co., has introduced Euvichol-Plus, an oral cholera vaccine encased in a low-density polyethylene (LDPE) unidose pack. This innovative packaging solution addresses several issues associated with traditional glass vials, including risks of breakage and challenges in storage, transportation, handling, and disposal.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cholera Vaccines Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cholera Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Beijing Minhai Biological Technology Co., Ltd., Bharat Biotech Ltd., Bio-Manguinhos, Biological E Ltd, BioVac by Ceva Santé Animale, Emergent BioSolutions Inc., GlaxoSmithKline plc, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co. Inc, Panacea Biotec Ltd, Sanofi S.A., SK Inc., Techinvention Lifecare Pvt. Ltd., and Valneva SE.

Market Segmentation & Coverage

This research report categorizes the Cholera Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Inactivated Vaccine
Live Attenuated Vaccine
Method of Administration
Injectable Vaccines
Oral Vaccines
End User
Government Vaccination Programs
Hospitals & Clinics
Age Group
Adults
Children
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year